
EC approves metastatic colorectal cancer combination regimen
The European Commission (EC) has approved a combination therapy for the treatment of metastatic colorectal cancer. Braftovi (encorafenib) has been approved in combination with cetuximab and FOLOX for the first-time treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC). The approval is based on the results from the Phase III BREAKWATER trial, which… Read More


